Cigna Raises 2026 EPS Outlook as New CEO Takes Helm, Specialty Growth Offsets PBM Transition Costs

Cigna’s senior leadership used the call to frame the quarter as a “proof‑of‑concept” for the company’s three‑pronged growth engine—Specialty & Care Services, Pharmacy Benefit Services, and the core health‑plan business—while signaling that the transition to a new CEO will be seamless.

“I’m pleased to report that the Cigna Group delivered strong performance in the first quarter… and we are raising our full‑year 2026 adjusted EPS outlook to at least $30.35,” said CEO David Cord‑ani, who capped his remarks with a personal note about his upcoming shift to Executive Chair.

Total revenues climbed to $68.5 billion, a modest rise that masks divergent segment dynamics. Evernorth, the company’s health‑services arm, posted $58.4 billion in revenue, up 9% year‑over‑year, and pretax adjusted earnings of $1.5 billion, a 2% gain that beat consensus.

The headline driver was Specialty and Care Services, which posted a 20% jump in pretax adjusted earnings to $1.1 billion. “We are seeing strong volume growth, higher adoption of biosimilars and specialty generics, and a meaningful contribution from our investment in Shields Health Solutions,” CFO Ann Dennison explained.

By contrast, Pharmacy Benefit Services (PBS) saw pretax adjusted earnings fall 28% to $394 million, a decline the company attributed to large client renewals that pushed a $150 million one‑time cost and to upfront investments needed for the upcoming rebate‑free Signature model. “These investments are weighted toward the back half of the year, and the trajectory remains consistent with our prior guidance,” Dennison added.

Cigna Healthcare, the health‑plan segment, generated $11.5 billion in revenue and $1.5 billion in pretax adjusted earnings, with a medical care ratio (MCR) of 79.8%, slightly below the 81% range the company had signaled. The modest miss was explained by “lower flu volumes and weather‑related care deferrals” and a higher proportion of bronze‑tier individual exchange members, which carry a lower MCR early in the year.

The earnings beat was further bolstered by a $322 million after‑tax special‑items charge—primarily a mix of tax and accounting adjustments—diluting the headline adjusted EPS of $7.79. Even with that hit, the adjusted EPS rose 16% YoY, reinforcing the company’s narrative of “steady execution in a dynamic operating environment.”

Strategic pivots featured heavily in the discussion. The company announced two portfolio‑shaping actions: an exit from its individual exchange business at year‑end 2026 and a strategic review of eviCore, its prior‑authorization platform. “Both decisions were proactive, not reactive,” said Evanko, emphasizing that the exchange exit frees “some capital” but is not material to the balance sheet, while the eviCore review reflects “the continued progress around standardization and automation of prior‑authorization processes.”

The most market‑moving initiative is the forthcoming Signature pharmacy‑benefit model, which promises a rebate‑free, transparent pricing structure that guarantees the lowest out‑of‑pocket cost for patients. “Our price‑assure capability guarantees patients the lowest possible out‑of‑pocket cost… whether that’s the negotiated price, the co‑pay, or a cash‑pay alternative,” Evanko told analysts.

He noted that the model will be standard for 50% of Evernorth members by the end of 2028, with the 2027 selling season still anchored in legacy contracts. The rollout appears on track, and client feedback has been “positive,” according to the executive.

Artificial intelligence and advanced analytics were highlighted as cross‑segment accelerators. Evanko cited “Agentic AI” in Specialty and Care Services to speed prescription processing, AI‑driven member communications in PBS, and predictive high‑cost claimant models in Cigna Healthcare that have already generated $2,000 per member per year in savings. “We do not use AI for clinical decision‑making, but it strengthens the decision quality of our highly experienced clinical teams,” he clarified.

Analyst questions probed the timing of the Signature rollout, the financial impact of the exchange exit, and the potential upside of eviCore. UBS’s A.J. Rice asked whether clients would need “more than the typical notice” to transition to the new PBM model.

Evanko replied that the model is still in the 2027 selling season, with “mid‑90s or better retention” and that “the transition is built into the normal renewal cycle.” Bank of America’s Kevin Fischbeck sought clarity on capital recouped from the exchange exit, receiving a measured response that the freed capital “is not particularly material” in the context of the group’s overall balance sheet. JPMorgan’s Lisa Gill pressed on the $150 million PBS cost, hearing that the bulk is tied to large client renewals and the Signature investment, with the run‑rate expected to normalize in the second half.

The market reacted positively. Cigna’s shares rose 2.6% in the session, extending a 6.4% weekly gain and a 6.2% year‑to‑date advance, even as the stock remains 15.7% below its 52‑week high. The stock’s outperformance underscores investor confidence that the company’s strategic refocusing and leadership change will not disrupt earnings momentum.

Looking ahead, the company reaffirmed its full‑year guidance. Adjusted EPS is now targeted at a minimum of $30.35, up from the prior $29.70 range. Evernorth’s full‑year adjusted income from operations is expected to be at least $6.9 billion, while Cigna Healthcare’s pretax adjusted earnings are projected at a minimum of $4.525 billion.

The firm anticipates second‑quarter adjusted EPS to represent roughly 25% of the full‑year outlook, with operating cash flow of $1.1 billion in Q1 and a debt‑to‑capitalization ratio of 42.3%, a 70‑basis‑point improvement year‑over‑year.

The leadership transition adds a layer of narrative intrigue. Evanko, a 30‑year Cigna veteran, pledged to “double‑down on data, advanced analytics and AI” and to “continue disciplined capital deployment.” Cord‑ani, in his final earnings call, praised the “steadfast commitment to put the customer at the center” and promised to remain engaged as Executive Chair.

In sum, Cigna’s first‑quarter performance blends solid top‑line growth, a clear strategic pivot toward specialty and AI‑enabled services, and a forward‑looking earnings upgrade—all while navigating a CEO succession that appears well‑orchestrated. The company’s ability to deliver on its Signature PBM promise and to monetize its specialty platform will be the key litmus tests for investors as 2026 unfolds.